Answers are grounded in this paper and cite their sources.
Children, as a special population, exhibit significant age-specific characteristics and inter-individual variability in drug metabolism due to the influences of physiological development and genetic factors, bringing challenges to the efficacy and safety of clinical medication. Traditional pharmacokinetic studies are difficult to conduct in children and are constrained by numerous ethical limitations. Physiologically Based Pharmacokinetic (PBPK) modeling, as a mechanistic modeling tool, can integrate pediatric developmental physiological parameters, enzyme kinetic characteristics, and genetic polymorphism data. It has gradually become an important tool for predicting pediatric drug metabolism and optimizing dosing regimens. This review summarizes the key enzymatic characteristics of pediatric drug metabolism and the technological pathways and current application status of PBPK models in assessing pediatric drug metabolism. It discusses the major challenges, such as uncertainties in parameter extrapolation and the lack of pediatric-specific data. It further elaborates on the practical value of PBPK models in optimizing dosing regimens, supporting pediatric clinical trial design, and aiding regulatory decision-making. Finally, it proposes future directions for development by integrating artificial intelligence and multi-omics data. This review aims to provide a theoretical basis and practical reference for precision dosing in children and to promote the broader application of PBPK models in the pediatric pharmaceutical field.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: